StatPearls [Internet].
Treasure Island (FL): StatPearls Publishing; 2021 Jan-.
Top results in this bookTable of Contents
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].
York (UK): Centre for Reviews and Dissemination (UK); 1995-.
Rheumatoid arthritis in adults: diagnosis and management.
National Guideline Centre (UK).
London: National Institute for Health and Care Excellence (UK); 2018 Jul. (NICE Guideline, No. 100.)
Molecular Imaging and Contrast Agent Database (MICAD) [Internet].
Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
Autoimmunity: From Bench to Bedside [Internet].
Anaya JM, Shoenfeld Y, Rojas-Villarraga A, et al., editors.
Bogota (Colombia): El Rosario University Press; 2013 Jul 18.
Drugs for the Management of Rheumatoid Arthritis: Clinical Evaluation [Internet].
Wells GA, Smith C, Hossain A, et al.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Mar. (CADTH Health Technology Assessment, No. 146.)
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].
Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
InformedHealth.org [Internet].
Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2006-.
Endotext [Internet].
Feingold KR, Anawalt B, Boyce A, et al., editors.
South Dartmouth (MA): MDText.com, Inc.; 2000-.
Clinical Review Report: sarilumab (Kevzara) [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 May.
Tocilizumab (Actemra): Adult Patients with Moderately to Severely Active Rheumatoid Arthritis [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug.
Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update [Internet].
Donahue KE, Gartlehner G, Schulman ER, et al.
Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Jul. (Comparative Effectiveness Review, No. 211.)
Golimumab (Simponi) IV: In Combination with Methotrexate (MTX) for the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Jul.
Madame Curie Bioscience Database [Internet].
Austin (TX): Landes Bioscience; 2000-2013.
Clinical Review Report: Upadacitinib (Rinvoq): (AbbVie): Indication: For the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Mar.
Changing Health Care Systems and Rheumatic Disease.
Institute of Medicine (US) Committee on Changing Health Care Systems and Rheumatic Disease; Manning FJ, Barondess JA, editors.
Washington (DC): National Academies Press (US); 1996.
Clinical Review Report: Baricitinib (Olumiant): (Eli Lilly Canada Inc.): Indication: For use in combination with methotrexate (MTX) for the treatment of adult patients with moderate to severe rheumatoid arthritis who have responded inadequately to one or more disease-modifying antirheumatic drugs (DMARDs). Baricitinib may also be used as monotherapy in cases of intolerance to MTX [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Sep.
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M, Archer R, Tosh J, et al.
Southampton (UK): NIHR Journals Library; 2016 Apr. (Health Technology Assessment, No. 20.35.)
Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation.
Malottki K, Barton P, Tsourapas A, et al.
Southampton (UK): NIHR Journals Library; 2011 Mar. (Health Technology Assessment, No. 15.14.)
Pharmacoeconomic Review Report: Baricitinib (Olumiant): (Eli Lilly Canada Inc.): Indication: For use in combination with methotrexate (MTX) for the treatment of adult patients with moderate to severe rheumatoid arthritis who have responded inadequately to one or more disease-modifying antirheumatic drugs (DMARDs). Baricitinib may also be used as monotherapy in cases of intolerance to MTX [Internet].
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on